Precision Biologics To Deliver Poster Presentations On Clinical And Scientific Programs At Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

BETHESDA, Md.--(BUSINESS WIRE)--Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, will present at the SITC 37th Annual Meeting (2022) in Boston, MA.

The first poster presentation will discuss the novel target for its NEO-201 monoclonal antibody and mechanism of action for this drug including the specific O-glycan epitope recognized by NEO-201 and that NEO-201 kills target cells expressing core 1 and/or extended core 1 O-glycans through Antibody-Dependent Cellular Cytotoxicity (ADCC)

The second poster presentation will discuss the ongoing Phase 2 clinical trial being conducted at the National Cancer Institute that combines NEO-201 with Pembrolizumab in patients with treatment refractory solid tumors. The study is enrolling patients at the National Cancer Institute, Bethesda, MD, with metastatic Non-Small Cell Lung Cancer (NSCLC), Head and Neck Cancers, Endometrial Cancer and Cervical Cancer, who have already been treated with checkpoint inhibitor therapy (including prior Keytruda). (https://clinicaltrials.gov/ct2/show/NCT03476681)

Posters will be presented in person at the at the Boston Convention and Exhibition Center on Thursday November 10^th, 2022.

To learn more about our clinical and scientific activity please stop by these two following posters:

1) Poster Number 55 (11:40AM-1:10PM and 7:30-9:30PM)

Title: Identification of the O-glycan epitope targeted by an anti-human carcinoma monoclonal antibody (mAb) NEO-201.

2) Poster Number 637 (11:40AM–1:10PM and 7:30–9:00PM)

Title: Phase II combining NEO-201 with Pembrolizumab in adults with chemo-resistant solid tumors.

About Precision Biologics

Founded in 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the detection and treatment of cancer. The company’s antibody drug candidates and diagnostics are designed to detect and target the tumor with minimal damage to healthy cells. Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today’s breakthrough technologies, the company is developing antibody therapeutics that could change the way we detect and treat cancer. For more information on Precision Biologics, please visit http://www.precision-biologics.com/.

Media:
RoseMarie Terenzio, rterenzio@kivvit.com, c: 917-913-7226